NCT02144077已完成3 期
A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 281
- 试验地点
- 1
- 主要终点
- Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDT
研究概览
简要总结
The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).
详细描述
The treatment comprises of up to 2 PDT cycles, each with two PDT sessions one week apart.
If 12 weeks after the the second PDT all lesions are completely cleared the patient will enter the follow-up phase. In case of remaining lesions the patient will receive a second PDT cycle starting on the same day.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to sign informed consent form; obtained in writing before starting any study procedures
- •Presence of 1-3 thin (≤2 mm thickness), clinically non-aggressive, primary BCC lesions (primary superficial, nodular, or mixed superficial/nodular) in the face/forehead, bald scalp, extremities and/or neck/trunk. Confirmation of non-aggressiveness and thickness of BCC through biopsies taken at screening for at least one lesion. Lesions non-eligible according to biopsy should timely be removed by surgery or cryotherapy
- •Diameters of lesions should range between ≥0.5cm and ≤2cm; total maximal treated area is 10cm² (including 0.5-1.0cm margin surrounding each lesion)
- •Target BCC lesions must be discrete and quantifiable and have to be located within 1-2 treatment areas
- •Free of significant physical abnormalities (eg tattoos, dermatoses) in potential treatment area that may cause difficulty with examination or final evaluation
- •Accept to abstain from extensive sunbathing and use of solarium during observer blind part. Patients with sunburn within treatment areas cannot be included until fully recovered
- •Healthy patients and patients with clinically stable medical conditions, including, but not limited to controlled hypertension, diabetes mellitus type II, hypercholesterolemia, and osteoarthritis, will be permitted to be included in study if their medication is not prohibited by protocol
- •Women of childbearing potential are permitted to participate in study only if they have a negative serum pregnancy test at screening and willingness to use a highly effective method of contraception during observer blind part
排除标准
- •History of hypersensitivity to 5-ALA or any ingredient of BF-200 ALA, MAL or any ingredient of Metvix®, including arachis oil, or to peanut or soya
- •Hypersensitivity to porphyrins
- •Current treatment with immunosuppression therapy
- •Presence of porphyria
- •Presence of BCC lesions on embryonic fusion planes (H-zone)
- •Presence of more than 3 BCCs
- •Presence of malignant or benign tumors of the skin other than non-aggressive BCC within the treatment area (eg malignant melanoma, squamous cell carcinoma (SCC), aggressive BCC clinically diagnosed at screening) within the last 12 weeks
- •Gorlin Syndrome or Xeroderma pigmentosum
- •Presence of photodermatoses
- •Treatment of lesions (actinic keratosis (AK), BCC, SCC, Bowens disease, melanoma) ≤12 weeks prior to first PDT, except physical treatments (eg cryosurgery, excision surgery) that will not be allowed ≤6 weeks prior to first PDT (Visit 2). Lesion(s) that seemed eligible clinically which could not be confirmed by biopsy, and which are located ≥10cm to an eligible lesion should timely be removed physically only
- •Presence of inherited or acquired coagulation defect
- •Start of intake of medication with hypericin or systemically-acting drugs with phototoxic or photoallergic potential within 8 weeks prior to screening
- •Clinically relevant cardiovascular, hepatic, renal, neurologic, endocrine, or other major systemic disease making implementation of protocol or interpretation of study results difficult
- •Evidence of clinically significant (CS), unstable medical conditions, eg:
- •Metastatic tumor or tumor with high probability of metastasis
- •Cardiovascular disease (New York Heart Association [NYHA] class III, IV)
- •Immunosuppressive condition
- •Hematologic, hepatic, renal, neurologic, or endocrine condition
- •Collagen-vascular condition
- •Gastrointestinal condition
- •Topical treatment with 5-ALA or MAL outside treatment area during the observer blind part
- •Any topical treatment including diclofenac and immunomodulatory agents (eg imiquimod, ingenol mebutate) 12 weeks prior to first PDT session and during observer blind part
- •Any physical treatment during the observer blind part within treated target areas with exception of lesion(s) determined non-eligible by biopsy
研究组 & 干预措施
BF-200 ALA
Active Comparator
Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
干预措施: BF-200 ALA (Drug)
methyl-aminolevulinate
Active Comparator
Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
干预措施: methyl-aminolevulinate (Drug)
结局指标
主要结局
Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDT
时间窗: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
Overall patient complete response rate assessed 12 weeks after the last PDT. The indicated values give the percentage of overall complete responders. An overall complete responder is defined as a patient in whom all treated lesions were cleared. The PP set is the primary analysis set for the analyses of the primary endpoint.
次要结局
- Cosmetic Outcome 12 Weeks After the Last PDT (Including Patients With a Baseline Sum Score >1)(12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).)
- Reduction of Lesion Area 12 Weeks After the Last PDT Compared to Baseline(12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).)
- Cosmetic Outcome 12 Weeks After Last PDT (Including Patients With a Sum Score of 0 at Baseline)(12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).)
- Lesion Complete Response Assessed 12 Weeks After the Last PDT(12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).)
- Patient Complete Response 12 Weeks After PDT-2(12 weeks after PDT-2 (=PDT cycle 1; please note: in this study 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) IMucopolysaccharidosis IHurlers SyndromeHurler-Scheie SyndromeNCT00912925Genzyme, a Sanofi Company45
已完成
3 期
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoMultiple Sclerosis, Relapsing-RemittingNCT00548405Genzyme, a Sanofi Company840
撤回
2 期
Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.Metastatic Colorectal CancerNCT03688230SFJ Pharmaceuticals X, LTD.
已完成
3 期
Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic TherapyActinic KeratosisNCT02799069Biofrontera Bioscience GmbH571
Unknown
3 期
Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis PatientsMultiple SclerosisNCT01333358Central Texas Neurology Consultants30